Indoco Remedies Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9szy6smfcfqnqrrq0jzq81oz.pdf

Key Takeaways


US Business: OAI Impact and Recovery Path

Aditi Panandikar: "some of the milestones we were to receive from clients for products made at this site. Those have got postponed."

Domestic Formulations: Chronic and Sub-Chronic Drive Growth

Aditi Panandikar: "anti-infective and respiratory have been the most challenging two therapies to predict for performance in the last three years or four years... there doesn't seem to be any kind of normalization frankly."

Europe: Poised for a Step-Up


Margins: Confident of 17.5% Despite Q1 Headwinds

Aditi Panandikar: "We feel pretty confident that we'll be able to for the full year go up to 17.5%."

Other Businesses and Initiatives


Regulatory and Remediation

Aditi Panandikar: "We are also, at this time, having constant communication back and forth with FDA, hoping to have a face-to-face or online call at some point to clearly understand their position and concerns because with 4 observations, we had not expected an OAI."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA marginAchieve 17.5%Full year FY24
US revenueINR280–300 croresFull year FY24
US quarterly run-rate rampGrow from INR50 crores to INR80 crores per quarter, with more in Q3 and Q4FY24
Europe revenueINR375–380 croresFull year FY24
India business growthMinimum 11–12% growthFull year FY24
Emerging markets turnaroundDramatic turnaround from a one-off Q1From Q2 FY24
Partner shift to FPPShift external partner to internal, not more than 3–4 monthsFrom decision date
New US solid oral launchesFew new launches from the other siteUnspecified, FY24

Key Metrics

MetricQ1 FY24
Consolidated revenue₹413.2 cr, +5% YoY
Domestic formulations revenue₹213 cr, +6.5% YoY
International formulations revenue₹159.7 cr, -9.9% YoY
API business revenue₹35.7 cr, +169.2% YoY
EBITDA₹62.9 cr, 15.2% margin vs 18.1% YoY
Profit after tax₹25.7 cr, 6.2% margin vs 9.5% YoY
Earnings per share₹2.81 vs ₹4.17 YoY
IPM rank and market share31st, 0.58% share (IQVIA Apr-Jun '23)
US business revenue₹51 cr (per analyst's math), -21.1% YoY
Europe business revenue₹79.4 cr, +2.1% YoY
Emerging markets revenue₹25.3 cr, -14.7% YoY
FY24 US revenue guidance₹280–300 cr
FY24 Europe revenue guidance₹375–380 cr
FY24 EBITDA margin guidance17.5% (revised from 18%)
Remediation cost (OAI-related)₹4 cr incurred in Q1, ~₹4 cr per quarter expected
New product introduction contribution₹6.5 cr, more than double YoY